Patients with chronic pain have symptoms of increased anxiety, depression and cognitive impairment. Patients with these chronic pain syndromes are underserved by existing approved medications, and are often users of unapproved psychedelic drugs and opiates for improving pain control.
Today, chronic pain sufferers are faced with a lack of options that often lead to a choice between highly addictive opioids or continued pain. Serotonin agonists have been shown to have potent effects in blocking painful sensations in animal models of several hard to treat painful syndromes like cluster headache, fibromyalgia, chemotherapy induced peripheral neuropathy.
These patients need better and safer treatments that can control pain and improve their quality of life. The neuropsychiatric and analgesic effects of 5-HT2C/A agonists are expected to contribute to better management of pain without the side effects of addiction, drowsiness, worsened cognition observed with current pain medications.
Bright Minds Biosciences is working with the National Institutes of Health to develop new non-opioid pain control medications.
